Nasdaq - Delayed Quote USD

Lord Abbett Multi-Asset Income R5 (LIXTX)

16.05

0.00

(0.00%)

At close: May 23 at 8:01:27 PM EDT

Make the Most of Your Retirement with These Top-Ranked Mutual Funds

Adding these three top-ranked, best-performing, and well-managed mutual funds to your retirement portfolio could maximize your returns.

Zacks 27 days ago

IIGCX

INIIX

INIVX
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether “initiated” cells that carry mutat

GlobeNewswire last month

LIXT

LIXTW
+34.11%
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100's Potential in Enhancing Cancer Immunotherapies- -Two Breakthrough Publications in Medical Journals, EMBO and Cancer Discovery,Supporting LIXTE’s Clinical Trial Program- PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”

GlobeNewswire last month

LIXT

LIXTW
+34.11%
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form

-- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company, today announced online publication of new pre-clinical data in BioXriv and International Journal of Pharmaceutics demonstrating how the Company’s lead clinical compound, LB-100, is converted into i

GlobeNewswire 2 months ago

LIXT

LIXTW
+34.11%
LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Company’s

GlobeNewswire 2 months ago

LIXT

LIXTW
+34.11%
3 Safe Utility Funds to Boost Your Portfolio Amid Soaring Inflation

Utility funds like BULIX, FSUTX and FKUTX are a safe bet during times of market volatility.

Zacks 3 months ago

BULIX

FKUQX

FKUTX
Lixte Biotechnology announces closing of $1.05M registered direct offering

LIXTE Biotechnology (LIXT) announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 434,784 shares of the company’s common stock at a purchase price of $2.415 per share. In addition, in a concurrent private placement, the company issued unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants have an exercise price of $2.29 per share and are exercis

TipRanks 3 months ago

LIXT

LIXTW
+34.11%
LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PASADENA, CALIF., Feb. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 434,784 shares of the Company’s common stock at a purchase price of $2.415 per share. In addition, in a concurrent private placement, the Company issue

GlobeNewswire 3 months ago

LIXT

LIXTW
+34.11%
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common stock at a purchase price of $2.415 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company wi

GlobeNewswire 3 months ago

LIXT

LIXTW
+34.11%
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the “SEC”) of the Company’s Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as the Company no longer intends to pursue a public o

GlobeNewswire 3 months ago

LIXT

LIXTW
+34.11%
3 Utility Funds to Buy as Consumer Sentiment Declines in January

Utility funds like FSUTX, BULIX and FKUTX are a safe bet during times of market volatility.

Zacks 4 months ago

BULIX

FSUTX

FKUQX
3 Top-Ranked Mutual Funds for Your Retirement

These three top-ranked, best-performing and well-managed funds can help you maximize your retirement portfolio returns.

Zacks 4 months ago

FEGIX

FEGOX

FEURX
US Penny Stocks To Watch In December 2024

As the U.S. market anticipates the Federal Reserve's decision on interest rates, stock futures are pointing to a higher open, suggesting a potential rebound from recent downturns. For investors looking beyond large-cap stocks, penny stocks—often representing smaller or newer companies—remain an intriguing area of exploration despite their historical connotations. These stocks can offer hidden value when backed by strong financials and growth potential, and this article will highlight three...

Simply Wall St. 5 months ago

PSHG

LIXT

LIXTW
+34.11%
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Investor Summit Group, an independent organization focused on creating networking opportunities for the MicroCap and SmallCap community, has announced that presentations from the August 20 Microcap ...

ACCESS Newswire 8 months ago

DCGO

SOTK

CVKD
3 Great Mutual Fund Picks for Your Retirement

Consider adding these three top-ranked, best-performing and well-managed mutual funds to your retirement portfolio if you are looking to maximize returns.

Zacks 8 months ago

BINCX

BISAX

BISMX
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Patent Covers Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent application number 16/467,721, titled, "Oxabicycloheptanes for Modulation of Immune Response,” for combining the Company’s LB-100 compound with v

GlobeNewswire 8 months ago

LIXT

LIXTW
+34.11%
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. (“Roche”) for treatment of unresponsive (MSI Low) metastatic colorectal cancer. As part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, L

GlobeNewswire 8 months ago

LIXT

LIXTW
+34.11%
LIXTE Biotechnology Provides Update On Recent Activities and Developments

-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy- -LIXTE to Present at Two Upcoming Investor Conferences- PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW),

GlobeNewswire 9 months ago

LIXT

LIXTW
+34.11%
LIXTE Biotechnology Holdings to Present at Two Investor Conferences

-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference- PASADENA, CALIF., Aug. 15, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will be presenting at two investor conferences: The Investor Summit Summer 2024 Virtual Conference Tuesday, August 20, 2024, at 2 p.m. EDT/

GlobeNewswire 9 months ago

LIXT

LIXTW
+34.11%
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

NEW YORK, NY / ACCESSWIRE / August 14, 2024 /Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company ...

ACCESS Newswire 9 months ago

LIXT

LIXTW
+34.11%

Performance Overview

Return	LIXTX	Category
YTD	+1.11%	+5.91%
1-Year	+9.38%	+18.59%
3-Year	+5.21%	+8.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lord Abbett Multi-Asset Income R5 (LIXTX)

Related Mutual Fund News

Make the Most of Your Retirement with These Top-Ranked Mutual Funds

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form

LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

3 Safe Utility Funds to Boost Your Portfolio Amid Soaring Inflation

Lixte Biotechnology announces closing of $1.05M registered direct offering

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

3 Utility Funds to Buy as Consumer Sentiment Declines in January

3 Top-Ranked Mutual Funds for Your Retirement

US Penny Stocks To Watch In December 2024

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

3 Great Mutual Fund Picks for Your Retirement

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Performance Overview